Annamaria Gulla

Has grant

Group leader

Candiolo Cancer Institute, FPO-IRCCS
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Exploiting phagocytosis checkpoints as novel immunotherapeutic targets in multiple myeloma

Open Date: 2022-01-01

Close Date: 2027-01-01

Grant: Close

Optimizing mechanisms for induction of immunogenic cell death to improve clinical outcome in high risk multiple myeloma patients

Open Date:

Close Date:

Grant: Close

Functional role of STING in bortezomib-induced antimyeloma immunity

Open Date:

Close Date:

Articles (7)

Transcription factors and their cofactors are major and selective nononcogene dependencies in multiple myeloma cells. By performing a gain-of-function perturbation screen in human multiple myeloma cell lines, we identified the inhibitor of DNA binding ( ID ) genes as putative suppressors of multiple myeloma cell fitness. Among them, ID2 was found to be downregulated in multiple myeloma patient cells and acted as a tumor suppressor by directly binding and repressing the basic helix-loop-helix factor TCF3, also known as E2A. Lower ID2 expression in multiple myeloma cells conferred a proliferative advantage by increasing TCF3 activity, leading to a dependency on this transcription factor. In contrast, ID2 overexpression reduced TCF3 binding to DNA, which resulted in cell-cycle arrest and a halt in multiple myeloma cell proliferation. The myeloma bone marrow milieu supported this process by further decreasing the expression of ID2 and enhancing TCF3 activity, partly via IL6, revealing a mechanism by which the tumor microenvironment affects multiple myeloma cell behavior. Significance: Multiple myeloma cells exploit the oncogenic and proliferative potential of TCF3 by downregulating the transcriptional regulator ID2, a process facilitated by the bone marrow microenvironment.

Year:

2026

Supplementary Figure S1. Discovery of ID2 as a putative tumor suppressor in MM. Supplementary Figure S2. ID2 expression causes cell cycle arrest in MM cells. Supplementary Figure S3. Induced ID2 expression in MM cells is associated with senescence-like features. Supplementary Figure S4. TCF3 is a highly expressed selective dependency in MM cells. Supplementary Figure S5. Depletion of TCF3 phenocopies effects of ID2 overexpression in MM cells. Supplementary Figure S6. The bone marrow milieu has a role in supporting TCF3 activity in MM.

Year:

2026

Supplementary Figure S4. Impact of pharmacological inhibition (ND-630 and ND-646) and ACC1 knockdown on MM cell viability, proliferation, and de novo lipogenesis (DNL) rates in MYC overexpressed MM cells.

Year:

2025

Purpose: In multiple myeloma, tumor cells reprogram metabolic pathways to sustain growth and monoclonal immunoglobulin production. This study examines acetyl-CoA carboxylase 1 ( ACC1 ), the enzyme driving the rate-limiting step in de novo lipogenesis, in multiple myeloma metabolic reprogramming, particularly in c- MYC ( MYC )–driven subtypes. Experimental Design: ACC1 expression was evaluated across multiple myeloma genetic subgroups, focusing on MYC translocations. Functional studies using ACC1 inhibitors and genetic knockdown assessed multiple myeloma cell growth, lipid synthesis, and metabolic homeostasis in vitro and in vivo . The role of MYC overexpression in ACC1 sensitivity was examined, with palmitate rescue experiments. Lipidomic analysis and assessments of endoplasmic reticulum (ER) stress, protein translation, and oxidative damage elucidated underlying mechanisms. Results: ACC1 was overexpressed in MYC -translocated multiple myeloma. Its inhibition or knockdown reduced multiple myeloma cell growth in vitro and in vivo , particularly in MYC- overexpressing cells. ACC1 knockdown suppressed de novo lipid synthesis, partially rescued by palmitate. Lipidomic disruptions increased cholesterol ester desaturation and altered phospholipid ratios, inducing ER stress, impaired translation, protein carbonylation, oxidative damage, and apoptosis. Conclusions: ACC1 is a metabolic vulnerability in MYC -driven multiple myeloma. Inhibiting ACC1 disrupts lipid homeostasis, induces ER stress, and causes oxidative damage, impairing cell survival. Targeting lipid synthesis pathways, especially in MYC -dependent subtypes, offers a promising therapeutic strategy for multiple myeloma.

Year:

2025

Purpose: BRD9 is a defining component of the noncanonical SWI/SNF complex, which regulates gene expression by controlling chromatin dynamics. Although recent studies have found an oncogenic role for BRD9 in multiple cancer types including multiple myeloma, its clinical significance and oncogenic mechanism have not yet been elucidated. Here, we sought to identify the clinical and biological impact of BRD9 in multiple myeloma, which may contribute to the development of novel therapeutic strategies. Experimental Design: We performed integrated analyses of BRD9 in vitro and in vivo using multiple myeloma cell lines and primary multiple myeloma cells in established preclinical models, which identified the molecular functions of BRD9 contributing to multiple myeloma cell survival. Results: We found that high BRD9 expression was a poor prognostic factor in multiple myeloma. Depleting BRD9 by genetic (shRNA) and pharmacologic (dBRD9-A; proteolysis-targeting chimera; BRD9 degrader) approaches downregulated ribosome biogenesis genes, decreased the expression of the master regulator MYC, and disrupted the protein-synthesis maintenance machinery, thereby inhibiting multiple myeloma cell growth in vitro and in vivo in preclinical models. Importantly, we identified that the expression of ribosome biogenesis genes was associated with the disease progression and prognosis of patients with multiple myeloma. Our results suggest that BRD9 promotes gene expression by predominantly occupying the promoter regions of ribosome biogenesis genes and cooperating with BRD4 to enhance the transcriptional function of MYC. Conclusions: Our study identifies and validates BRD9 as a novel therapeutic target in preclinical models of multiple myeloma, which provides the framework for the clinical evaluation of BRD9 degraders to improve patient outcome.

Year:

2025

Purpose: BRD9 is a defining component of the noncanonical SWI/SNF complex, which regulates gene expression by controlling chromatin dynamics. Although recent studies have found an oncogenic role for BRD9 in multiple cancer types including multiple myeloma, its clinical significance and oncogenic mechanism have not yet been elucidated. Here, we sought to identify the clinical and biological impact of BRD9 in multiple myeloma, which may contribute to the development of novel therapeutic strategies. Experimental Design: We performed integrated analyses of BRD9 in vitro and in vivo using multiple myeloma cell lines and primary multiple myeloma cells in established preclinical models, which identified the molecular functions of BRD9 contributing to multiple myeloma cell survival. Results: We found that high BRD9 expression was a poor prognostic factor in multiple myeloma. Depleting BRD9 by genetic (shRNA) and pharmacologic (dBRD9-A; proteolysis-targeting chimera; BRD9 degrader) approaches downregulated ribosome biogenesis genes, decreased the expression of the master regulator MYC, and disrupted the protein-synthesis maintenance machinery, thereby inhibiting multiple myeloma cell growth in vitro and in vivo in preclinical models. Importantly, we identified that the expression of ribosome biogenesis genes was associated with the disease progression and prognosis of patients with multiple myeloma. Our results suggest that BRD9 promotes gene expression by predominantly occupying the promoter regions of ribosome biogenesis genes and cooperating with BRD4 to enhance the transcriptional function of MYC. Conclusions: Our study identifies and validates BRD9 as a novel therapeutic target in preclinical models of multiple myeloma, which provides the framework for the clinical evaluation of BRD9 degraders to improve patient outcome.

Year:

2024

Year:

2023

Collaborators (13)

Na Liu

researcher

University of Bergen

NORWAY
View details

Francesca Scionti

Senior Research Technologist

Magna Graecia University

ITALY
View details

Adam Sperling

Assistant Professor

Stanford University

UNITED STATES
View details

Charles B. Epstein

Broad Institute

UNITED STATES
View details

Massimo Loda

Chair

Weill Cornell Medical College

UNITED STATES
View details

Anil Aktas Samur

Senior Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Jonathan Henninger

Assistant Professor

Carnegie Mellon University

UNITED STATES
View details

Eugenio Morelli

Assistant Professor

Università degli Studi di Torino

ITALY
View details

jun qi

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Mehmet Samur

Senior Research Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Giorgio Inghirami

Professor

Weill Cornell Medical College

UNITED STATES
View details

Raphael Szalat

Assistant professor

Boston University

UNITED STATES
View details

Lawrence Boise

Professor

Emory University

UNITED STATES
View details